A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HDM2005 in Patients With Advanced Solid Tumors
Latest Information Update: 11 Jun 2025
At a glance
- Drugs HDM 2005 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hangzhou Zhongmei Huadong Pharmaceutical
Most Recent Events
- 11 Jun 2025 New trial record